Viracta Therapeutics announced that its lead development program, Nana-val, has completed Stage 2 enrollment into the relapsed or refractory Epstein-Barr virus-positive peripheral T-cell lymphoma cohort of the NAVAL-1 trial. “Given the nature of this serious life-threatening condition and absence of EBV-targeted treatments today, our goal is to bring Nana-val to patients with relapsed or refractory EBV-positive PTCL as quickly as possible,” said Darrel Cohen, M.D., Ph.D., Chief Medical Officer of Viracta. “The completion of Stage 2 enrollment of the PTCL cohort in NAVAL-1 is a major milestone for the Nana-val clinical development program. We would like to acknowledge the dedication of our study execution team and the commitment of our investigators for this achievement. We look forward to building upon our previously published positive data from the Phase 1b/2 clinical trial and reporting topline PTCL cohort data from Stage 1 of the NAVAL-1 trial in the second quarter of 2024. Additionally, we plan to meet with FDA in mid-2024 to align on requirements for accelerated approval of Nana-val in this orphan indication.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VIRX:
- Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
- Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Viracta Therapeutics price target lowered to $4 from $10 at H.C. Wainwright
- Viracta Therapeutics provides anticipated 2024 milestones
- Viracta Therapeutics Provides Clinical Update and Outlook for 2024